Company / Cash & Equivalents
Fortress Biotech, Inc. Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$79.4M
FY2025
5-year range
$57.3M / $305.7M
FY2021-FY2025
Trend
+38.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents returned to growth in FY2025 after 3 years of decline, reaching $79M.
Based on SEC 10-K filings.
$79M in FY2025 with a 5-year CAGR of -10.3%.
Remained stable around $79M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -23.6%
- 5-Year CAGR
- -10.3%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -10.3%, indicating a declining trend.
- In FY2025, cash & equivalents increased 38.6% year-over-year.
- Peak cash & equivalents was recorded in FY2021.
- Lowest cash & equivalents in the period was in FY2024.
Company context
Key Data Points
- Altman Z-Score -1.10 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $79.4M | +38.6% |
| FY2024 | $57.3M | -29.2% |
| FY2023 | $80.9M | -54.6% |
| FY2022 | $178.3M | -41.7% |
| FY2021 | $305.7M | +123.4% |
| FY2020 | $136.9M | +0.0% |
| FY2019 | $136.9M | +108.9% |
| FY2018 | $65.5M | -25.8% |
| FY2017 | $88.3M | -10.1% |
| FY2016 | $98.2M | -1.3% |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026